We have located links that may give you full text access.
The impact of the fluconazole trailing effect on the persistence of Candida albicans bloodstream infection when treated with fluconazole.
Clinical Microbiology and Infection 2024 March 24
OBJECTIVES: The trailing effect of Candida species is a phenomenon characterized by reduced but persistent growth at antifungal concentrations above the minimal inhibitory concentration (MIC). We assessed the impact of trailing growth on the persistence of Candida albicans candidemia in patients receiving fluconazole therapy.
METHODS: We retrospectively investigated candidemia isolates at three hospitals in southern Taiwan between 2013 and 2020. Patients treated with fluconazole for fluconazole-susceptible C. albicans candidemia were enrolled. The degree of trailing was determined as the average growth above the MIC divided by the measured growth at the lowest drug concentration using the EUCAST method and classified into four categories, residual (0.1-5%), slight (6-10%), moderate (11-15%), and heavy trailers (>15%).
RESULTS: Among isolates from 190 patients, the proportions of heavy trailers at 24 h, 48 h, and 72 h were 63.7% (121/190), 63.2% (120/190), and 74.7% (142/190), respectively. Persistent candidemia was observed in 17 (8.9 %) patients. The proportion of persistent C. albicans candidemia in heavy trailing isolates at 48 h was higher than in isolates without heavy trailing (13.3% [16/120] vs. 1.4% [1/70], p=0.007). A multivariate analysis showed that immunosuppression (odds ratio [OR] = 7.92; 95% confidence interval [CI]: 2.38-26.39, p=0.001), hospitalization days after the index date of C. albicans identification (OR=1.03; 95% CI: 1.01-1.05, p=0.011) and heavy trailing isolates at 48 h (OR=10.04; 95% CI: 1.27-79.88, p=0.029) were independent factors for persistent candidemia.
CONCLUSIONS: The current study revealed that heavy trailing in C. albicans isolates is associated with persistent candidemia in patients receiving fluconazole treatment.
METHODS: We retrospectively investigated candidemia isolates at three hospitals in southern Taiwan between 2013 and 2020. Patients treated with fluconazole for fluconazole-susceptible C. albicans candidemia were enrolled. The degree of trailing was determined as the average growth above the MIC divided by the measured growth at the lowest drug concentration using the EUCAST method and classified into four categories, residual (0.1-5%), slight (6-10%), moderate (11-15%), and heavy trailers (>15%).
RESULTS: Among isolates from 190 patients, the proportions of heavy trailers at 24 h, 48 h, and 72 h were 63.7% (121/190), 63.2% (120/190), and 74.7% (142/190), respectively. Persistent candidemia was observed in 17 (8.9 %) patients. The proportion of persistent C. albicans candidemia in heavy trailing isolates at 48 h was higher than in isolates without heavy trailing (13.3% [16/120] vs. 1.4% [1/70], p=0.007). A multivariate analysis showed that immunosuppression (odds ratio [OR] = 7.92; 95% confidence interval [CI]: 2.38-26.39, p=0.001), hospitalization days after the index date of C. albicans identification (OR=1.03; 95% CI: 1.01-1.05, p=0.011) and heavy trailing isolates at 48 h (OR=10.04; 95% CI: 1.27-79.88, p=0.029) were independent factors for persistent candidemia.
CONCLUSIONS: The current study revealed that heavy trailing in C. albicans isolates is associated with persistent candidemia in patients receiving fluconazole treatment.
Full text links
Related Resources
Trending Papers
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Prevention and treatment of ischaemic and haemorrhagic stroke in people with diabetes mellitus: a focus on glucose control and comorbidities.Diabetologia 2024 April 17
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Eosinophilic Esophagitis: Clinical Pearls for Primary Care Providers and Gastroenterologists.Mayo Clinic Proceedings 2024 April
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app